Literature DB >> 28126357

Hepatoblastoma.

Divya Sharma1, Girish Subbarao2, Romil Saxena3.   

Abstract

Hepatoblastoma is the most common primary malignant hepatic tumor of infancy and childhood, occurring predominantly in the first two years of life. The management of hepatoblastoma has changed markedly over the last 3 decades; neoadjuvant chemotherapy is now standard, particularly in unresectable tumors resulting in considerable preoperative tumor shrinkage and sometimes near total ablation of the tumor. A 20 month old infant was incidentally found to have a 7.6cm right sided retroperitoneal tumor on routine screening ultrasonography for left ureteral stenosis. Serum alpha fetoprotein was elevated. Biopsy revealed hepatoblastoma, mixed epithelial and embryonal type without mesenchymal elements. He underwent neoadjuvant chemotherapy. Although the tumor had decreased considerably in size, close proximity to major vascular structures precluded safe resection. Liver transplantation was performed; the explanted liver showed complete tumor necrosis with no residual malignancy. The postoperative course was uncomplicated and he is continuing on sixth cycle of chemotherapy.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Mixed epithelial mesenchymal hepatoblastoma; Pure fetal hepatoblastoma; Small cell undifferentiated hepatoblastoma; Teratoid hepatoblastoma

Mesh:

Year:  2016        PMID: 28126357     DOI: 10.1053/j.semdp.2016.12.015

Source DB:  PubMed          Journal:  Semin Diagn Pathol        ISSN: 0740-2570            Impact factor:   3.464


  33 in total

Review 1.  Hepatoblastoma: current knowledge and promises from preclinical studies.

Authors:  Diego F Calvisi; Antonio Solinas
Journal:  Transl Gastroenterol Hepatol       Date:  2020-07-05

Review 2.  Problematic lesions in cirrhotic liver mimicking hepatocellular carcinoma.

Authors:  Myeong-Jin Kim; Sunyoung Lee; Chansik An
Journal:  Eur Radiol       Date:  2019-02-20       Impact factor: 5.315

3.  Genetic variations in base excision repair pathway genes and risk of hepatoblastoma: a seven-center case-control study.

Authors:  Zhenjian Zhuo; Ao Lin; Jiao Zhang; Huitong Chen; Yong Li; Zhonghua Yang; Li Li; Suhong Li; Jiwen Cheng; Jing He
Journal:  Am J Cancer Res       Date:  2021-03-01       Impact factor: 6.166

4.  Repeat hepatectomy for pediatric recurrent chemotherapy-resistant hepatoblastoma: a report of 18 cases.

Authors:  Xiaoran Li; Zheng Wang; Dongpo Zhang; Di Zhao; Jindong Ye; Weihong Duan; Liuxin Duan; Quanda Liu
Journal:  J Cancer Res Clin Oncol       Date:  2022-08-29       Impact factor: 4.322

5.  Chrysotoxene induces apoptosis of human hepatoblastoma HepG2 cells in vitro and in vivo via activation of the mitochondria-mediated apoptotic signaling pathway.

Authors:  Chunqing Dou; Mingming Han; Bao Zhang; Liyuan Sun; Xin Jin; Tao Li
Journal:  Oncol Lett       Date:  2018-01-25       Impact factor: 2.967

Review 6.  Application of photodynamic therapy for liver malignancies.

Authors:  Heng Zou; Fusheng Wang; Jiang-Jiao Zhou; Xi Liu; Qing He; Cong Wang; Yan-Wen Zheng; Yu Wen; Li Xiong
Journal:  J Gastrointest Oncol       Date:  2020-04

7.  Enhanced antitumor activity of combined megestrol acetate and arsenic trioxide treatment in liver cancer cells.

Authors:  Yan Xia; Xianhao Liu; Beibei Liu; Xiaoshi Zhang; Geng Tian
Journal:  Exp Ther Med       Date:  2018-02-28       Impact factor: 2.447

8.  Molecular Mechanisms of Hepatoblastoma.

Authors:  Yi Zhang; Antonio Solinas; Stefano Cairo; Matthias Evert; Xin Chen; Diego F Calvisi
Journal:  Semin Liver Dis       Date:  2021-01-20       Impact factor: 6.115

9.  Common and Rare Histological Variants of Hepatoblastoma in Children: A Pathological Diagnosis and Review of the Literature.

Authors:  Sushma Bharti; Jyotsna Naresh Bharti; Arvind Sinha; Taruna Yadav
Journal:  Gastrointest Tumors       Date:  2021-02-04

10.  Different anaesthesia methods affect the development of hepatoblastoma after platelet activation.

Authors:  Guoxiong Fei; Meili Cao; Chunlin Ge; Yan Xie
Journal:  Int J Exp Pathol       Date:  2021-01-07       Impact factor: 1.925

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.